BioSpace News Archive

Lexaria Bioscience Corp., a global innovator in drug delivery platforms announces the results of the 2022 Annual Meeting.

Lucira has submitted for FDA emergency use authorization (EUA), with plans to introduce this new test as the nation adapts to an endemic coronavirus coincident with seasonal flu viruses.

Propanc Biopharma, Inc. announced that Chief Scientific Officer and Co-Founder, Dr Julian Kenyon MD, MB, ChB, believes the reduced toxicity of PRP compared to standard treatment approaches will impact cancer patient lives significantly.

Animal studies have been used extensively over the years to model the effect of medicinal compounds on the human body.

Harbour BioMed (the “Company”, HKEX: 02142), today announced the progress of its dual MOA of CTLA-4 inhibition and Treg depletion, next-generation fully human heavy-chain antibody (HBM4003) with studies of monotherapy and combination therapy with anti-PD-1 antibody.

MyOme, a clinical whole genome platform analysis company, today announced new data on a cross ancestry polygenic risk score (caPRS) for breast cancer that will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.

Perimeter Medical Imaging AI, Inc. announced the appointment of Chris Scott as Chief Financial Officer, effective immediately.

Trethera Corporation (“Trethera”), announces that an independent safety review committee has unanimously recommended further trial advancement following review of the favorable results from the company’s Phase 1a dose escalation clinical trial of TRE-515, its first-in-class deoxycytidine kinase (“dCK”) inhibitor.

Indivior PLC (LON: INDV) announces the enrollment of the first patient in the Phase 2b study of AEF0117 for the treatment of cannabis use disorder (CUD).

Todos Medical, Ltd. announced that its majority-owned subsidiary 3CL Pharma, Ltd. reported a Day 26 update from an ongoing 60-day case study by Dr. Lee Morgentaler of a 3CL protease cleanse with Tollovid, a 3CL protease inhibitor dietary supplement, in a patient who originally contracted COVID in March 2021 and experienced symptoms of Long COVID.